Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant factor VIIa: a universal hemostatic agent?

John V Lloyd1, J Heinrich Joist

  • 1Division of Hematology, Institute of Medical and Veterinary Science, Department of Clinical and Experimental Pharmacology, University of Adelaide, 1 Box 14 PO Rundle Mall, Adelaide, 5051, Australia.

Current Hematology Reports
|August 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigation of a link between raised levels of pepsinogen in blood as a mediator of in-vitro clot lysis in acid and a cause of abnormal factor XIII screening tests.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2014
Same author

Partial and severe factor XI deficiency in South Australia and the usefulness of factor XI mutation analysis for diagnosis.

Pathology·2008
Same author

In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results.

British journal of haematology·2007
Same author

Aspirin sensitivity of platelet aggregation in diabetes mellitus.

Diabetes research and clinical practice·2005
Same author

Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven).

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2004
Same author

Apparent cellulitis with a prolonged APTT. Activated partial thromboplastin time.

Journal of the Royal Society of Medicine·2003

Recombinant factor VIIa (rVIIa) shows promise for treating bleeding in hemophilia and other conditions. Further studies are needed to confirm its effectiveness as a universal hemostatic agent.

Area of Science:

  • Hematology
  • Pharmacology
  • Clinical Medicine

Background:

  • Recombinant factor VIIa (rVIIa) is established for treating hemorrhage in hemophilia patients with inhibitors.
  • Emerging evidence suggests rVIIa efficacy in diverse bleeding disorders beyond hemophilia.

Purpose of the Study:

  • To review the expanding therapeutic applications of rVIIa.
  • To identify areas requiring further clinical investigation for rVIIa use.

Main Methods:

  • Literature review of studies on rVIIa in various bleeding conditions.
  • Analysis of case reports and clinical observations regarding rVIIa effectiveness.

Main Results:

  • rVIIa has demonstrated effectiveness in inherited hemophilia A/B with inhibitors and acquired hemophilia A.

Related Experiment Videos

  • rVIIa shows potential in factor VII deficiency, thrombocytopenia, Glanzmann's thrombasthenia, and liver disease.
  • rVIIa has controlled massive hemorrhage unresponsive to conventional treatments in some cases.

    • Conclusions:

    • rVIIa is considered a potential universal hemostatic agent.
    • Further prospective, controlled studies are essential to validate rVIIa's efficacy in specific severe bleeding disorders.
    • Investigating rVIIa in severe thrombocytopenia, von Willebrand disease, platelet activation defects, and factor deficiencies (V, X, II, fibrinogen) is warranted.